Trials / Completed
CompletedNCT04532294
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
A First-in-Human, Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to investigate the safety and tolerability of BGB-DXP593 administered intravenously as a single dose in healthy participants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGB DXP593 | Administered intravenously (IV) as specified in the treatment arm |
| DRUG | Placebo | Placebo to match BGB-DXP593 |
Timeline
- Start date
- 2020-09-08
- Primary completion
- 2021-02-13
- Completion
- 2021-02-13
- First posted
- 2020-08-31
- Last updated
- 2024-10-26
- Results posted
- 2022-01-27
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT04532294. Inclusion in this directory is not an endorsement.